Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of a shiny sun and deliciously cool breeze wafting through the serene Pharmalot campus. Our short person has left for the schoolhouse, our official mascot is slumbering at our feet, and our coffee kettle is whistling a familiar tune. All that needs to be done is to now dig in for another busy day. On that note, here are a few items of interest. Hope you conquer the world today and, as always, drop us a line if you run across something saucy or fascinating …

After years of frustration, Vertex (VRTX) Pharmaceuticals (VRTX) struck a deal with the U.K. government to supply its cystic fibrosis medicines, capping an end to a dispute that had become a symbol of the growing clash between cash-strapped governments and drug makers over the rising prices for medicines, STAT reports. The agreement covers all cystic fibrosis treatments sold by Vertex, including a new triple-combination therapy once it is licensed in the U.K., although pricing was not disclosed.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy